Vascular Stent Market by Product Type (Balloon-Expandable Stents, Self-Expanding Stents), Material (Metallic Stents, Polymeric Stents), Delivery System, Application, End User - Global Forecast 2025-2032
Description
The Vascular Stent Market was valued at USD 10.92 billion in 2024 and is projected to grow to USD 11.49 billion in 2025, with a CAGR of 5.48%, reaching USD 16.73 billion by 2032.
An integrative framing of technological, clinical, and procurement dynamics shaping vascular stent development and stakeholder decision-making across care pathways
The vascular stent landscape sits at the convergence of medical device innovation, evolving clinical protocols, and shifting regulatory frameworks. Advances in device design, materials science, and deployment techniques are reshaping clinician preferences and patient outcomes. At the same time, payer dynamics and hospital procurement strategies are driving greater scrutiny of value, safety, and long-term performance. This introduction synthesizes the technological, clinical, and commercial forces currently influencing the vascular stent sector and frames the subsequent sections that examine structural shifts, policy impacts, segmentation nuances, regional differentials, and competitive behaviors.
Contextualizing recent developments, the industry narrative has moved beyond incremental design enhancements toward integrated systems thinking: devices are being evaluated not only for acute procedural success but also for long-term vessel patency, biocompatibility, and ease of deployment across diverse anatomies. Clinicians increasingly demand solutions that balance deliverability with durable outcomes, while health systems prioritize devices that reduce total episode costs and readmission risk. Against this backdrop, the following analysis explores the most consequential shifts and their implications for manufacturers, providers, and strategic investors.
How material science, imaging advances, and outcome-focused procurement are converging to redefine device selection, clinical adoption, and competitive differentiation
The vascular stent sector is undergoing transformative shifts catalyzed by material innovation, device architecture, and the integration of adjunctive therapies. Emerging biodegradable polymer technologies and hybrid metallic-polymeric constructs are prompting clinicians to reassess long-term risk–benefit profiles, leading to evolving adoption patterns across patient cohorts. Simultaneously, improvements in imaging modalities and intraprocedural guidance have enabled more precise deployment, reducing complications and expanding the range of anatomies treatable with endovascular approaches. These technical advances are not isolated; they interact with payer-driven emphasis on outcomes and the growing appetite among providers for devices that support shorter length-of-stay and faster recovery trajectories.
Shifts in clinical guidelines, influenced by expanding real-world evidence, are enabling broader indications for certain stent types while imposing stricter post-market surveillance and follow-up protocols. Moreover, the market is experiencing an uptick in modular delivery systems and platform technologies that permit incremental upgrades without wholesale replacement of infrastructure. This modularity supports faster iterative improvements and accelerates time-to-clinic for next-generation features. As a result, competition is increasingly centered on system-level value propositions rather than singular product attributes, prompting established manufacturers and new entrants alike to pursue partnerships that combine device performance with data-driven care pathways and training programs.
Assessing the strategic implications of 2025 tariff adjustments on supply chain resilience, sourcing strategies, and procurement negotiations across the vascular stent value chain
New trade policy measures and tariff adjustments implemented in 2025 have introduced important considerations for supply chain management, procurement planning, and pricing strategies across the vascular stent value chain. Manufacturers that previously relied on geographically concentrated component production faced immediate pressures to reassess sourcing decisions and to evaluate alternative logistics routes. These shifts accelerated conversations about onshoring critical manufacturing steps, diversifying supplier bases, and reconfiguring inventory buffers to mitigate exposure to tariff-induced cost volatility. Consequently, procurement teams within health systems are grappling with the implications for long-term contracts and total cost of ownership calculations.
The cumulative impact of tariffs extends beyond immediate input costs; it also affects strategic decisions around regional manufacturing footprints and partnership models. OEMs with vertically integrated operations or with preexisting regional production capacity were better positioned to absorb short-term disruptions, whereas firms dependent on cross-border just-in-time supply chains encountered margin compression or the need to renegotiate commercial terms. In response, a number of stakeholders prioritized supply chain resilience by qualifying multiple suppliers for critical components, investing in quality assurance across regions, and exploring toll-manufacturing arrangements to preserve market access while managing compliance obligations. These adjustments have reshaped negotiation dynamics with buyers, who increasingly demand transparency around origin, traceability, and contingency planning as part of procurement evaluations.
A multidimensional segmentation perspective revealing how device type, material science, delivery architecture, clinical application, and care setting collectively shape adoption and strategy
A nuanced segmentation analysis reveals how product type, material composition, delivery system, clinical application, and end-user context intersect to shape adoption trajectories and commercial strategies. Based on product type, the clinical trade-off between balloon-expandable stents and self-expanding stents continues to hinge on lesion characteristics, vessel size, and operator preference, with procedural planning dictating device selection. Based on material, the distinction between metallic stents and polymeric stents-subdivided into biodegradable and non-biodegradable polymers-introduces differential considerations for long-term vessel response, imaging artifact, and regulatory pathways. Transitioning from metallic platforms to polymeric constructs requires manufacturers to validate degradation profiles, biocompatibility, and sustained mechanical support in diverse vascular beds.
Based on delivery system, differences among bare metal stents, covered stents, and drug-eluting stents produce diverging clinical outcomes and reimbursement conversations, particularly in high-risk lesion sets and complex anatomies. Based on application, clinical demand varies substantially across coronary artery disease, gastrointestinal disease, and peripheral artery disease, with peripheral indications further segmented by lower extremities and upper extremities and each presenting unique anatomical and durability challenges that influence device design and trial endpoints. Based on end user, the dynamics of adoption differ between ambulatory surgical centers, cardiac centers, and hospitals; ambulatory settings prioritize efficiency and rapid turnover, cardiac centers focus on specialized support for complex interventions, and hospitals balance broad procedural coverage with inpatient care capabilities. Intersecting these segmentation axes reveals clear pockets of unmet need where specific device characteristics align with clinician requirements and reimbursement incentives, and it highlights opportunities for tailored clinical evidence generation and targeted commercialization strategies.
Regional variations in regulatory regimes, reimbursement priorities, and clinical adoption that determine differentiated market access strategies and evidence needs worldwide
Regional dynamics continue to exert a powerful influence on regulatory pathways, reimbursement structures, and commercial priorities across the vascular stent landscape. In the Americas, providers and payers emphasize outcome-based procurement and total episode cost accountability, which drives demand for devices that demonstrate reductions in reintervention rates and procedural complications. The regulatory environment across the region also places a premium on robust post-market surveillance, prompting manufacturers to invest in registries and real-world evidence programs to support sustained adoption. These activities are often coupled with clinical education initiatives to accelerate procedural proficiency and to demonstrate system-level value.
In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable reimbursement policies create a mosaic of access pathways, requiring manufacturers to adopt region-specific market entry strategies and evidence generation plans. While some countries in this region prioritize rapid adoption of innovative technologies through accelerated pathways, others rely on conservative assessment models that emphasize long-term outcome data. Across the Asia-Pacific region, high-volume patient populations, growing interventional cardiology and radiology infrastructure, and active domestic manufacturing clusters are fostering rapid uptake of novel stent platforms. However, adoption patterns are moderated by price sensitivity, local clinical practice variations, and differing insurance coverage models. Across all regions, companies that customize their go-to-market approach to align product value propositions with local clinical priorities, procurement cycles, and regulatory expectations are more likely to achieve sustainable penetration.
How innovation-driven competition, strategic alliances, and portfolio optimization are redefining market positioning, commercialization, and post-market engagement
Competitive behavior in the vascular stent sector is being shaped by product innovation, strategic partnerships, and a renewed emphasis on comprehensive value propositions. Established firms continue to leverage broad clinical trial programs, longitudinal registries, and global sales networks to defend market positions, while emerging entrants are differentiating through niche indications, novel materials, or disruptive delivery mechanisms. Collaborations between device makers and imaging or software companies are increasingly common, reflecting the industry’s shift toward integrated procedural ecosystems that enhance placement accuracy and post-procedural follow-up.
Moreover, strategic M&A and licensing arrangements remain important levers for filling portfolio gaps and accelerating access to new technologies or geographic markets. Some companies are prioritizing vertical integration of manufacturing capabilities to enhance control over critical inputs and to improve responsiveness to regulatory or tariff-driven disruptions. Others are forming focused alliances with clinical centers of excellence to co-develop training curricula and real-world evidence programs that support reimbursement discussions. Across competitive strategies, success is contingent on aligning R&D priorities with clear clinical differentiators and building scalable commercial models that accommodate diverse customer segments and regional requirements.
Practical strategic initiatives for manufacturers and providers to strengthen supply resilience, evidence generation, and commercial execution while driving durable competitive advantage
Industry leaders should prioritize a set of actionable initiatives that strengthen resilience, accelerate adoption, and maximize long-term clinical impact. First, invest in diversified manufacturing and qualified suppliers to reduce exposure to trade-policy shocks and to ensure continuity of supply. Integrate quality systems and supplier audits across regions to maintain consistent device performance and regulatory compliance. Second, develop evidence strategies that pair randomized data with pragmatic registries and real-world endpoints to address payer concerns about long-term outcomes and to support differentiated reimbursement narratives. Third, design modular platform strategies that allow incremental feature enhancements without requiring full system replacements, enabling more rapid clinical iteration and easier training for operators.
Additionally, pursue targeted collaborations with imaging and digital health partners to create procedure-centric ecosystems that enhance deployment precision and longitudinal patient monitoring. Tailor commercial models to end-user needs by offering flexible contracting, outcome-linked pricing pilots, and bundled service offerings that align device performance with hospital efficiency objectives. Finally, prioritize clinician training and proctoring programs to shorten adoption curves for complex anatomies and ensure consistent procedural outcomes. These combined actions will help manufacturers and providers navigate evolving clinical expectations, regulatory demands, and procurement pressures while creating durable competitive advantage.
A rigorous evidence synthesis and triangulation methodology combining regulatory records, clinical literature, and expert validation to underpin strategic insights and regional interpretations
This analysis synthesizes publicly available regulatory guidance, peer-reviewed clinical literature, device approvals, and observed commercial practices to construct a comprehensive view of the vascular stent landscape. Data inputs included device design specifications, material classifications, procedural trends reported in clinical journals, and documented changes to trade and reimbursement policies. The research approach emphasized triangulation: corroborating technical claims from product literature with independent clinical outcomes and cross-referencing procurement behaviors observed in health system communications with documented payer policy shifts. Where possible, regulatory filings and post-market surveillance summaries were reviewed to assess safety signals and durability metrics.
Qualitative validation was achieved through consultations with clinical experts, supply chain professionals, and health economics specialists to contextualize empirical findings and to interpret regional differences in adoption. The methodology prioritized transparency in inference, explicitly noting areas where evidence remains limited and where further prospective studies would be valuable. This structured approach supports robust insights while recognizing the inherent variability across patient populations, operator experience, and regional regulatory regimes.
Synthesis of technological, operational, and policy forces that will determine which organizations capture clinical adoption and deliver measurable value in evolving care models
In conclusion, the vascular stent sector stands at an inflection point characterized by converging technological advances, heightened expectations for demonstrable outcomes, and evolving supply chain realities. The interplay between innovative materials, modular delivery platforms, and enhanced imaging guidance is expanding clinical possibilities while increasing the importance of targeted evidence generation and clinician education. Concurrently, trade policy shifts and regional regulatory diversity underscore the need for supply chain agility and market-specific commercialization strategies. Together, these forces favor organizations that combine robust technical differentiation with disciplined operational resilience and clear value communication to payers and providers.
Moving forward, stakeholders who invest in diversified sourcing, integrated evidence strategies, and partnerships that extend beyond the device to procedural ecosystems will be best positioned to capture new clinical opportunities and to mitigate policy-driven disruptions. The recommendations outlined in this executive summary are intended to inform decision-making across R&D, manufacturing, regulatory affairs, and commercial teams as they refine strategies to navigate a dynamic and increasingly outcome-focused environment.
Please Note: PDF & Excel + Online Access - 1 Year
An integrative framing of technological, clinical, and procurement dynamics shaping vascular stent development and stakeholder decision-making across care pathways
The vascular stent landscape sits at the convergence of medical device innovation, evolving clinical protocols, and shifting regulatory frameworks. Advances in device design, materials science, and deployment techniques are reshaping clinician preferences and patient outcomes. At the same time, payer dynamics and hospital procurement strategies are driving greater scrutiny of value, safety, and long-term performance. This introduction synthesizes the technological, clinical, and commercial forces currently influencing the vascular stent sector and frames the subsequent sections that examine structural shifts, policy impacts, segmentation nuances, regional differentials, and competitive behaviors.
Contextualizing recent developments, the industry narrative has moved beyond incremental design enhancements toward integrated systems thinking: devices are being evaluated not only for acute procedural success but also for long-term vessel patency, biocompatibility, and ease of deployment across diverse anatomies. Clinicians increasingly demand solutions that balance deliverability with durable outcomes, while health systems prioritize devices that reduce total episode costs and readmission risk. Against this backdrop, the following analysis explores the most consequential shifts and their implications for manufacturers, providers, and strategic investors.
How material science, imaging advances, and outcome-focused procurement are converging to redefine device selection, clinical adoption, and competitive differentiation
The vascular stent sector is undergoing transformative shifts catalyzed by material innovation, device architecture, and the integration of adjunctive therapies. Emerging biodegradable polymer technologies and hybrid metallic-polymeric constructs are prompting clinicians to reassess long-term risk–benefit profiles, leading to evolving adoption patterns across patient cohorts. Simultaneously, improvements in imaging modalities and intraprocedural guidance have enabled more precise deployment, reducing complications and expanding the range of anatomies treatable with endovascular approaches. These technical advances are not isolated; they interact with payer-driven emphasis on outcomes and the growing appetite among providers for devices that support shorter length-of-stay and faster recovery trajectories.
Shifts in clinical guidelines, influenced by expanding real-world evidence, are enabling broader indications for certain stent types while imposing stricter post-market surveillance and follow-up protocols. Moreover, the market is experiencing an uptick in modular delivery systems and platform technologies that permit incremental upgrades without wholesale replacement of infrastructure. This modularity supports faster iterative improvements and accelerates time-to-clinic for next-generation features. As a result, competition is increasingly centered on system-level value propositions rather than singular product attributes, prompting established manufacturers and new entrants alike to pursue partnerships that combine device performance with data-driven care pathways and training programs.
Assessing the strategic implications of 2025 tariff adjustments on supply chain resilience, sourcing strategies, and procurement negotiations across the vascular stent value chain
New trade policy measures and tariff adjustments implemented in 2025 have introduced important considerations for supply chain management, procurement planning, and pricing strategies across the vascular stent value chain. Manufacturers that previously relied on geographically concentrated component production faced immediate pressures to reassess sourcing decisions and to evaluate alternative logistics routes. These shifts accelerated conversations about onshoring critical manufacturing steps, diversifying supplier bases, and reconfiguring inventory buffers to mitigate exposure to tariff-induced cost volatility. Consequently, procurement teams within health systems are grappling with the implications for long-term contracts and total cost of ownership calculations.
The cumulative impact of tariffs extends beyond immediate input costs; it also affects strategic decisions around regional manufacturing footprints and partnership models. OEMs with vertically integrated operations or with preexisting regional production capacity were better positioned to absorb short-term disruptions, whereas firms dependent on cross-border just-in-time supply chains encountered margin compression or the need to renegotiate commercial terms. In response, a number of stakeholders prioritized supply chain resilience by qualifying multiple suppliers for critical components, investing in quality assurance across regions, and exploring toll-manufacturing arrangements to preserve market access while managing compliance obligations. These adjustments have reshaped negotiation dynamics with buyers, who increasingly demand transparency around origin, traceability, and contingency planning as part of procurement evaluations.
A multidimensional segmentation perspective revealing how device type, material science, delivery architecture, clinical application, and care setting collectively shape adoption and strategy
A nuanced segmentation analysis reveals how product type, material composition, delivery system, clinical application, and end-user context intersect to shape adoption trajectories and commercial strategies. Based on product type, the clinical trade-off between balloon-expandable stents and self-expanding stents continues to hinge on lesion characteristics, vessel size, and operator preference, with procedural planning dictating device selection. Based on material, the distinction between metallic stents and polymeric stents-subdivided into biodegradable and non-biodegradable polymers-introduces differential considerations for long-term vessel response, imaging artifact, and regulatory pathways. Transitioning from metallic platforms to polymeric constructs requires manufacturers to validate degradation profiles, biocompatibility, and sustained mechanical support in diverse vascular beds.
Based on delivery system, differences among bare metal stents, covered stents, and drug-eluting stents produce diverging clinical outcomes and reimbursement conversations, particularly in high-risk lesion sets and complex anatomies. Based on application, clinical demand varies substantially across coronary artery disease, gastrointestinal disease, and peripheral artery disease, with peripheral indications further segmented by lower extremities and upper extremities and each presenting unique anatomical and durability challenges that influence device design and trial endpoints. Based on end user, the dynamics of adoption differ between ambulatory surgical centers, cardiac centers, and hospitals; ambulatory settings prioritize efficiency and rapid turnover, cardiac centers focus on specialized support for complex interventions, and hospitals balance broad procedural coverage with inpatient care capabilities. Intersecting these segmentation axes reveals clear pockets of unmet need where specific device characteristics align with clinician requirements and reimbursement incentives, and it highlights opportunities for tailored clinical evidence generation and targeted commercialization strategies.
Regional variations in regulatory regimes, reimbursement priorities, and clinical adoption that determine differentiated market access strategies and evidence needs worldwide
Regional dynamics continue to exert a powerful influence on regulatory pathways, reimbursement structures, and commercial priorities across the vascular stent landscape. In the Americas, providers and payers emphasize outcome-based procurement and total episode cost accountability, which drives demand for devices that demonstrate reductions in reintervention rates and procedural complications. The regulatory environment across the region also places a premium on robust post-market surveillance, prompting manufacturers to invest in registries and real-world evidence programs to support sustained adoption. These activities are often coupled with clinical education initiatives to accelerate procedural proficiency and to demonstrate system-level value.
In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable reimbursement policies create a mosaic of access pathways, requiring manufacturers to adopt region-specific market entry strategies and evidence generation plans. While some countries in this region prioritize rapid adoption of innovative technologies through accelerated pathways, others rely on conservative assessment models that emphasize long-term outcome data. Across the Asia-Pacific region, high-volume patient populations, growing interventional cardiology and radiology infrastructure, and active domestic manufacturing clusters are fostering rapid uptake of novel stent platforms. However, adoption patterns are moderated by price sensitivity, local clinical practice variations, and differing insurance coverage models. Across all regions, companies that customize their go-to-market approach to align product value propositions with local clinical priorities, procurement cycles, and regulatory expectations are more likely to achieve sustainable penetration.
How innovation-driven competition, strategic alliances, and portfolio optimization are redefining market positioning, commercialization, and post-market engagement
Competitive behavior in the vascular stent sector is being shaped by product innovation, strategic partnerships, and a renewed emphasis on comprehensive value propositions. Established firms continue to leverage broad clinical trial programs, longitudinal registries, and global sales networks to defend market positions, while emerging entrants are differentiating through niche indications, novel materials, or disruptive delivery mechanisms. Collaborations between device makers and imaging or software companies are increasingly common, reflecting the industry’s shift toward integrated procedural ecosystems that enhance placement accuracy and post-procedural follow-up.
Moreover, strategic M&A and licensing arrangements remain important levers for filling portfolio gaps and accelerating access to new technologies or geographic markets. Some companies are prioritizing vertical integration of manufacturing capabilities to enhance control over critical inputs and to improve responsiveness to regulatory or tariff-driven disruptions. Others are forming focused alliances with clinical centers of excellence to co-develop training curricula and real-world evidence programs that support reimbursement discussions. Across competitive strategies, success is contingent on aligning R&D priorities with clear clinical differentiators and building scalable commercial models that accommodate diverse customer segments and regional requirements.
Practical strategic initiatives for manufacturers and providers to strengthen supply resilience, evidence generation, and commercial execution while driving durable competitive advantage
Industry leaders should prioritize a set of actionable initiatives that strengthen resilience, accelerate adoption, and maximize long-term clinical impact. First, invest in diversified manufacturing and qualified suppliers to reduce exposure to trade-policy shocks and to ensure continuity of supply. Integrate quality systems and supplier audits across regions to maintain consistent device performance and regulatory compliance. Second, develop evidence strategies that pair randomized data with pragmatic registries and real-world endpoints to address payer concerns about long-term outcomes and to support differentiated reimbursement narratives. Third, design modular platform strategies that allow incremental feature enhancements without requiring full system replacements, enabling more rapid clinical iteration and easier training for operators.
Additionally, pursue targeted collaborations with imaging and digital health partners to create procedure-centric ecosystems that enhance deployment precision and longitudinal patient monitoring. Tailor commercial models to end-user needs by offering flexible contracting, outcome-linked pricing pilots, and bundled service offerings that align device performance with hospital efficiency objectives. Finally, prioritize clinician training and proctoring programs to shorten adoption curves for complex anatomies and ensure consistent procedural outcomes. These combined actions will help manufacturers and providers navigate evolving clinical expectations, regulatory demands, and procurement pressures while creating durable competitive advantage.
A rigorous evidence synthesis and triangulation methodology combining regulatory records, clinical literature, and expert validation to underpin strategic insights and regional interpretations
This analysis synthesizes publicly available regulatory guidance, peer-reviewed clinical literature, device approvals, and observed commercial practices to construct a comprehensive view of the vascular stent landscape. Data inputs included device design specifications, material classifications, procedural trends reported in clinical journals, and documented changes to trade and reimbursement policies. The research approach emphasized triangulation: corroborating technical claims from product literature with independent clinical outcomes and cross-referencing procurement behaviors observed in health system communications with documented payer policy shifts. Where possible, regulatory filings and post-market surveillance summaries were reviewed to assess safety signals and durability metrics.
Qualitative validation was achieved through consultations with clinical experts, supply chain professionals, and health economics specialists to contextualize empirical findings and to interpret regional differences in adoption. The methodology prioritized transparency in inference, explicitly noting areas where evidence remains limited and where further prospective studies would be valuable. This structured approach supports robust insights while recognizing the inherent variability across patient populations, operator experience, and regional regulatory regimes.
Synthesis of technological, operational, and policy forces that will determine which organizations capture clinical adoption and deliver measurable value in evolving care models
In conclusion, the vascular stent sector stands at an inflection point characterized by converging technological advances, heightened expectations for demonstrable outcomes, and evolving supply chain realities. The interplay between innovative materials, modular delivery platforms, and enhanced imaging guidance is expanding clinical possibilities while increasing the importance of targeted evidence generation and clinician education. Concurrently, trade policy shifts and regional regulatory diversity underscore the need for supply chain agility and market-specific commercialization strategies. Together, these forces favor organizations that combine robust technical differentiation with disciplined operational resilience and clear value communication to payers and providers.
Moving forward, stakeholders who invest in diversified sourcing, integrated evidence strategies, and partnerships that extend beyond the device to procedural ecosystems will be best positioned to capture new clinical opportunities and to mitigate policy-driven disruptions. The recommendations outlined in this executive summary are intended to inform decision-making across R&D, manufacturing, regulatory affairs, and commercial teams as they refine strategies to navigate a dynamic and increasingly outcome-focused environment.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Growing adoption of bioresorbable vascular scaffolds with optimized drug delivery profiles
- 5.2. Advances in polymer-free drug-eluting stents reducing inflammation risks in coronary interventions
- 5.3. Integration of intravascular imaging and artificial intelligence for personalized stent placement planning
- 5.4. Development of 3D printed patient-specific stent implants to improve anatomical conformity and outcomes
- 5.5. Emerging nanocoating technologies enhancing endothelial healing and reducing restenosis rates in stents
- 5.6. Rise of distal radial access techniques influencing stent design for improved procedural safety and comfort
- 5.7. Increasing regulatory approvals of novel magnesium-based bioresorbable stents across multiple global markets
- 5.8. Cost pressures driving adoption of off-patent drug-eluting stents in emerging economies with growing patient pools
- 5.9. Expansion of peripheral artery disease treatment demand fueling innovation in iliac and femoral stent designs
- 5.10. Integration of remote monitoring and digital therapeutics for post-stent implantation patient management pathways
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Vascular Stent Market, by Product Type
- 8.1. Balloon-Expandable Stents
- 8.2. Self-Expanding Stents
- 9. Vascular Stent Market, by Material
- 9.1. Metallic Stents
- 9.2. Polymeric Stents
- 9.2.1. Biodegradable Polymers
- 9.2.2. Non-Biodegradable Polymers
- 10. Vascular Stent Market, by Delivery System
- 10.1. Bare Metal Stents
- 10.2. Covered Stents
- 10.3. Drug Eluting Stents
- 11. Vascular Stent Market, by Application
- 11.1. Coronary Artery Disease
- 11.2. Gastrointestinal Disease
- 11.3. Peripheral Artery Disease
- 11.3.1. Lower Extremities
- 11.3.2. Upper Extremities
- 12. Vascular Stent Market, by End User
- 12.1. Ambulatory Surgical Centers
- 12.2. Cardiac Centers
- 12.3. Hospitals
- 13. Vascular Stent Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Vascular Stent Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Vascular Stent Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Abbott Laboratories
- 16.3.2. Amaranth Medical, Inc.
- 16.3.3. Artivion Inc.
- 16.3.4. B. Braun SE
- 16.3.5. Becton, Dickinson and Company
- 16.3.6. Biotronik SE & Co. KG
- 16.3.7. Blue Sail Medical Co., Ltd
- 16.3.8. Boston Scientific Corporation
- 16.3.9. Cardinal Health, Inc.
- 16.3.10. Cook Group Incorporated
- 16.3.11. Elixir Medical Corporation
- 16.3.12. Endologix LLC
- 16.3.13. iVascular, S.L.U
- 16.3.14. Kaneka Corporation
- 16.3.15. Kyoto Medical Planning Co., Ltd.
- 16.3.16. Lepu Medical Technology(Beijing)Co.,Ltd.
- 16.3.17. Lombard Medical Ltd.
- 16.3.18. Medtronic PLC
- 16.3.19. Meril Life Sciences Pvt. Ltd
- 16.3.20. Microport Scientific Corporation
- 16.3.21. Otsuka Medical Devices Co., Ltd.
- 16.3.22. Purple MicroPort Cardiovascular Pvt. Ltd
- 16.3.23. Sahajanand Medical Technologies Limited
- 16.3.24. Stryker Corporation
- 16.3.25. Terumo Corporation
- 16.3.26. Translumina GmbH
- 16.3.27. W. L. Gore & Associates, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
